Regencell Bioscience Holdings Limited (RGC) has stated its intention to launch three liquid-based standardized Traditional Chinese Medicine (TCM) formulae candidates for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in Hong Kong. However, the company explicitly acknowledges that the clinical treatment results for these formulae are "not supported by controlled clinical data or trials".1
Despite the absence of controlled clinical data, RGC may pursue alternative regulatory pathways for launching its TCM products in Hong Kong. The regulatory landscape for TCM products can differ significantly from that of Western pharmaceuticals, with varying requirements depending on product classification and intended use.
Potential strategies for RGC to launch its TCM products in Hong Kong without controlled clinical data include:
- Marketing as Health Supplements or Food Products: If the products do not make specific medical claims that would classify them as drugs, they might be registered and sold as health supplements or food products. These categories typically have less stringent clinical trial requirements compared to conventional medicines. For instance, in the context of dietary supplements, regulatory bodies like the FDA in the US do not typically approve products for safety, effectiveness, or labeling before sale, placing the onus on companies to ensure safety standards.2 Hong Kong's regulations for health supplements also focus on aspects like metallic contamination, microbiological guidelines, and proper labeling, rather than requiring extensive clinical trials for efficacy.2
- Practitioner-Prescribed Products: RGC's SEC filings mention that the TCM formulae are derived from a "TCM Brain Theory" developed by a TCM Practitioner, Mr. Sik-Kee Au, and that the company conducted an internal "efficacy trial" involving 28 patients in Hong Kong under the TCM Practitioner's treatment.1 It is possible that the products are intended for use under the direct supervision and prescription of registered TCM practitioners, which could fall under a different regulatory framework than over-the-counter sales, potentially requiring less rigorous clinical trial data for market entry.
- Claims Based on Traditional Use or Observational Data: RGC's internal efficacy trial, while not a controlled clinical trial, reportedly demonstrated improvements in patients' conditions.1 The company might leverage such observational data and claims based on traditional use, rather than seeking approval as a new drug that would necessitate full-scale, controlled clinical trials. This approach aligns with how some TCM products are regulated, particularly in mainland China, where certain "Traditional Chinese Medicine Pieces" are exempt from clinical testing if they comply with Good Manufacturing Practice (GMP) and national pharmacopoeia standards.3
Regarding the "by December 2024" timeline, RGC's unaudited condensed consolidated interim financial results for the six months ended December 31, 2024, show a significant decrease in selling and marketing expenses to $7,329, down from $97,062 in the prior year.1 This reduction in marketing expenditure could suggest that a major product launch had not yet occurred or was delayed by the end of 2024. However, the financial filing itself does not explicitly confirm the launch status of these specific TCM products by that date.
